These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 17309133)

  • 1. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
    Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.
    Wolfe F; Michaud K; Anderson J; Urbansky K
    Arthritis Rheum; 2004 Feb; 50(2):372-9. PubMed ID: 14872478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
    Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.
    Mohan AK; Coté TR; Block JA; Manadan AM; Siegel JN; Braun MM
    Clin Infect Dis; 2004 Aug; 39(3):295-9. PubMed ID: 15306993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antirheumatic drugs and the risk of tuberculosis.
    Brassard P; Kezouh A; Suissa S
    Clin Infect Dis; 2006 Sep; 43(6):717-22. PubMed ID: 16912945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
    Jacobsson LT; Turesson C; Gülfe A; Kapetanovic MC; Petersson IF; Saxne T; Geborek P
    J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
    Slifman NR; Gershon SK; Lee JH; Edwards ET; Braun MM
    Arthritis Rheum; 2003 Feb; 48(2):319-24. PubMed ID: 12571839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
    Arkema EV; Jonsson J; Baecklund E; Bruchfeld J; Feltelius N; Askling J;
    Ann Rheum Dis; 2015 Jun; 74(6):1212-7. PubMed ID: 24608401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers.
    Kim EM; Uhm WS; Bae SC; Yoo DH; Kim TH
    J Rheumatol; 2011 Oct; 38(10):2218-23. PubMed ID: 21844149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
    Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
    Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.